ID   L2GL1_HUMAN             Reviewed;        1064 AA.
AC   Q15334; A7MBM7; O00188; Q58F11; Q86UK6;
DT   18-APR-2006, integrated into UniProtKB/Swiss-Prot.
DT   22-SEP-2009, sequence version 3.
DT   28-JUN-2023, entry version 181.
DE   RecName: Full=Lethal(2) giant larvae protein homolog 1;
DE            Short=LLGL;
DE   AltName: Full=DLG4;
DE   AltName: Full=Hugl-1;
DE   AltName: Full=Human homolog to the D-lgl gene protein;
GN   Name=LLGL1; Synonyms=DLG4, HUGL, HUGL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   INTERACTION WITH MYOSIN II HEAVY CHAIN, AND VARIANTS GLY-148 AND HIS-550.
RC   TISSUE=Brain;
RX   PubMed=7542763;
RA   Strand D.J., Unger S., Corvi R., Hartenstein K., Schenkel H., Kalmes A.,
RA   Merdes G., Neumann B., Kreig-Schneider F., Coy J.F., Poustka A., Schwab M.,
RA   Mechler B.;
RT   "A human homologue of the Drosophila tumour suppressor gene l(2)gl maps to
RT   17p11.2-12 and codes for a cytoskeletal protein that associates with
RT   nonmuscle myosin II heavy chain.";
RL   Oncogene 11:291-301(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLY-148.
RC   TISSUE=Brain;
RX   PubMed=8565641; DOI=10.1159/000134167;
RA   Koyama K., Fukushima Y., Inazawa J., Tomotsune D., Takahashi N.,
RA   Nakamura Y.;
RT   "The human homologue of the murine Llglh gene (LLGL) maps within the Smith-
RT   Magenis syndrome region in 17p11.2.";
RL   Cytogenet. Cell Genet. 72:78-82(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLY-148.
RC   TISSUE=Fetal brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INTERACTION WITH PARD6B/PAR-6 AND PRKCI/APKC, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION AT SER-663.
RX   PubMed=12725730; DOI=10.1016/s0960-9822(03)00244-6;
RA   Yamanaka T., Horikoshi Y., Sugiyama Y., Ishiyama C., Suzuki A., Hirose T.,
RA   Iwamatsu A., Shinohara A., Ohno S.;
RT   "Mammalian Lgl forms a protein complex with PAR-6 and aPKC independently of
RT   PAR-3 to regulate epithelial cell polarity.";
RL   Curr. Biol. 13:734-743(2003).
RN   [5]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15735678; DOI=10.1038/sj.onc.1208520;
RA   Schimanski C.C., Schmitz G., Kashyap A., Bosserhoff A.K., Bataille F.,
RA   Schafer S.C., Lehr H.A., Berger M.R., Galle P.R., Strand S., Strand D.;
RT   "Reduced expression of Hugl-1, the human homologue of Drosophila tumour
RT   suppressor gene lgl, contributes to progression of colorectal cancer.";
RL   Oncogene 24:3100-3109(2005).
RN   [6]
RP   FUNCTION, TISSUE SPECIFICITY, AND INVOLVEMENT IN COLORECTAL CANCER AND
RP   MELANOMA.
RX   PubMed=16170365; DOI=10.1038/sj.onc.1209008;
RA   Kuphal S., Wallner S., Schimanski C.C., Bataille F., Hofer P., Strand S.,
RA   Strand D., Bosserhoff A.K.;
RT   "Expression of Hugl-1 is strongly reduced in malignant melanoma.";
RL   Oncogene 25:103-110(2006).
RN   [7]
RP   INTERACTION WITH DCAF1.
RX   PubMed=20644714; DOI=10.1371/journal.pbio.1000422;
RA   Tamori Y., Bialucha C.U., Tian A.G., Kajita M., Huang Y.C., Norman M.,
RA   Harrison N., Poulton J., Ivanovitch K., Disch L., Liu T., Deng W.M.,
RA   Fujita Y.;
RT   "Involvement of Lgl and Mahjong/VprBP in cell competition.";
RL   PLoS Biol. 8:E1000422-E1000422(2010).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
CC   -!- FUNCTION: Cortical cytoskeleton protein found in a complex involved in
CC       maintaining cell polarity and epithelial integrity. Involved in the
CC       regulation of mitotic spindle orientation, proliferation,
CC       differentiation and tissue organization of neuroepithelial cells.
CC       Involved in axonogenesis through RAB10 activation thereby regulating
CC       vesicular membrane trafficking toward the axonal plasma membrane.
CC       {ECO:0000269|PubMed:15735678, ECO:0000269|PubMed:16170365}.
CC   -!- SUBUNIT: Associated with nonmuscle myosin II heavy chain. Interacts
CC       with PRKCI/aPKC, PARD6B/Par-6 and PARD6A. Interacts with STX4A (By
CC       similarity). Interacts with RAB10 (GDP-bound form); the interaction is
CC       direct and promotes RAB10 association with membranes and activation
CC       through competition with the Rab inhibitor GDI1 (By similarity).
CC       Interacts with DCAF1. {ECO:0000250, ECO:0000269|PubMed:12725730,
CC       ECO:0000269|PubMed:20644714, ECO:0000269|PubMed:7542763}.
CC   -!- SUBCELLULAR LOCATION: Early endosome membrane {ECO:0000250}. Golgi
CC       apparatus, trans-Golgi network membrane {ECO:0000250}. Golgi apparatus
CC       membrane {ECO:0000250}. Cell projection, axon {ECO:0000250}. Cytoplasm,
CC       cytoskeleton {ECO:0000269|PubMed:12725730, ECO:0000269|PubMed:7542763}.
CC       Note=Localized to the lateral membrane during the polarization and
CC       formation cell-cell contacts. Enriched in developing axons (By
CC       similarity). {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in brain, kidney, and muscle but is
CC       barely seen in heart and placenta. Down-regulated or lost in all cell
CC       lines and in most of the tumor samples analyzed. Loss was associated
CC       with advanced stage of the disease. {ECO:0000269|PubMed:15735678,
CC       ECO:0000269|PubMed:16170365, ECO:0000269|PubMed:7542763}.
CC   -!- PTM: Phosphorylated at least at Ser-663 by PRKCI.
CC       {ECO:0000269|PubMed:12725730}.
CC   -!- MISCELLANEOUS: Down-regulation of LLGL1 is associated with the
CC       progression of colorectal cancer and melanoma. Located within the
CC       Smith-Magenis syndrome region on chromosome 17; deleted in patients
CC       with this syndrome.
CC   -!- MISCELLANEOUS: Expression increases cell adhesion and decreases cell
CC       migration. Substitutes for Drosophila l(2)gl tumor suppressor function
CC       in vivo.
CC   -!- SIMILARITY: Belongs to the WD repeat L(2)GL family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA19516.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X86371; CAA60130.1; -; mRNA.
DR   EMBL; D50550; BAA19516.1; ALT_FRAME; mRNA.
DR   EMBL; BC028037; AAH28037.1; -; mRNA.
DR   EMBL; BC151838; AAI51839.1; -; mRNA.
DR   CCDS; CCDS32586.1; -.
DR   PIR; I38171; I38171.
DR   RefSeq; NP_004131.3; NM_004140.3.
DR   AlphaFoldDB; Q15334; -.
DR   SMR; Q15334; -.
DR   BioGRID; 110183; 154.
DR   ComplexPortal; CPX-6188; Scribble cell polarity complex, DLG5-LLGL1-SCRIB variant.
DR   ComplexPortal; CPX-6189; Scribble cell polarity complex, DLG4-LLGL1-SCRIB variant.
DR   ComplexPortal; CPX-6190; Scribble cell polarity complex, DLG3-LLGL1-SCRIB variant.
DR   ComplexPortal; CPX-6191; Scribble cell polarity complex, DLG2-LLGL1-SCRIB variant.
DR   ComplexPortal; CPX-6192; Scribble cell polarity complex, DLG1-LLGL1-SCRIB variant.
DR   CORUM; Q15334; -.
DR   IntAct; Q15334; 52.
DR   MINT; Q15334; -.
DR   STRING; 9606.ENSP00000321537; -.
DR   GlyCosmos; Q15334; 1 site, 2 glycans.
DR   GlyGen; Q15334; 1 site, 2 O-linked glycans (1 site).
DR   iPTMnet; Q15334; -.
DR   PhosphoSitePlus; Q15334; -.
DR   SwissPalm; Q15334; -.
DR   BioMuta; LLGL1; -.
DR   DMDM; 259016343; -.
DR   EPD; Q15334; -.
DR   jPOST; Q15334; -.
DR   MassIVE; Q15334; -.
DR   MaxQB; Q15334; -.
DR   PaxDb; Q15334; -.
DR   PeptideAtlas; Q15334; -.
DR   ProteomicsDB; 60533; -.
DR   Antibodypedia; 13463; 223 antibodies from 26 providers.
DR   DNASU; 3996; -.
DR   Ensembl; ENST00000316843.9; ENSP00000321537.4; ENSG00000131899.12.
DR   Ensembl; ENST00000640494.2; ENSP00000492144.1; ENSG00000284137.2.
DR   GeneID; 3996; -.
DR   KEGG; hsa:3996; -.
DR   MANE-Select; ENST00000316843.9; ENSP00000321537.4; NM_004140.4; NP_004131.4.
DR   UCSC; uc002gsp.4; human.
DR   AGR; HGNC:6628; -.
DR   CTD; 3996; -.
DR   DisGeNET; 3996; -.
DR   GeneCards; LLGL1; -.
DR   HGNC; HGNC:6628; LLGL1.
DR   HPA; ENSG00000131899; Tissue enhanced (brain).
DR   MIM; 600966; gene.
DR   neXtProt; NX_Q15334; -.
DR   OpenTargets; ENSG00000131899; -.
DR   PharmGKB; PA30396; -.
DR   VEuPathDB; HostDB:ENSG00000131899; -.
DR   eggNOG; KOG1983; Eukaryota.
DR   GeneTree; ENSGT00950000182906; -.
DR   HOGENOM; CLU_005214_0_0_1; -.
DR   InParanoid; Q15334; -.
DR   OMA; HACTILI; -.
DR   OrthoDB; 415950at2759; -.
DR   PhylomeDB; Q15334; -.
DR   TreeFam; TF314585; -.
DR   PathwayCommons; Q15334; -.
DR   SignaLink; Q15334; -.
DR   SIGNOR; Q15334; -.
DR   BioGRID-ORCS; 3996; 19 hits in 1160 CRISPR screens.
DR   ChiTaRS; LLGL1; human.
DR   GeneWiki; LLGL1; -.
DR   GenomeRNAi; 3996; -.
DR   Pharos; Q15334; Tbio.
DR   PRO; PR:Q15334; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q15334; protein.
DR   Bgee; ENSG00000131899; Expressed in C1 segment of cervical spinal cord and 93 other tissues.
DR   ExpressionAtlas; Q15334; baseline and differential.
DR   Genevisible; Q15334; HS.
DR   GO; GO:0005912; C:adherens junction; NAS:ComplexPortal.
DR   GO; GO:0030424; C:axon; IEA:UniProtKB-SubCell.
DR   GO; GO:0030864; C:cortical actin cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; TAS:ProtInc.
DR   GO; GO:0031901; C:early endosome membrane; ISS:UniProtKB.
DR   GO; GO:0000137; C:Golgi cis cisterna; ISS:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0032588; C:trans-Golgi network membrane; ISS:UniProtKB.
DR   GO; GO:0005096; F:GTPase activator activity; ISS:UniProtKB.
DR   GO; GO:0045159; F:myosin II binding; IBA:GO_Central.
DR   GO; GO:0019901; F:protein kinase binding; IDA:UniProtKB.
DR   GO; GO:0005198; F:structural molecule activity; TAS:ProtInc.
DR   GO; GO:0007409; P:axonogenesis; ISS:UniProtKB.
DR   GO; GO:0030866; P:cortical actin cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0051294; P:establishment of spindle orientation; IBA:GO_Central.
DR   GO; GO:0045197; P:establishment or maintenance of epithelial cell apical/basal polarity; NAS:ComplexPortal.
DR   GO; GO:0006887; P:exocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0006893; P:Golgi to plasma membrane transport; ISS:UniProtKB.
DR   GO; GO:0065003; P:protein-containing complex assembly; IDA:UniProtKB.
DR   GO; GO:0032878; P:regulation of establishment or maintenance of cell polarity; IBA:GO_Central.
DR   GO; GO:0008593; P:regulation of Notch signaling pathway; IBA:GO_Central.
DR   GO; GO:0050708; P:regulation of protein secretion; IBA:GO_Central.
DR   Gene3D; 2.130.10.10; YVTN repeat-like/Quinoprotein amine dehydrogenase; 1.
DR   InterPro; IPR000664; Lethal2_giant.
DR   InterPro; IPR013577; LLGL2.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   InterPro; IPR001680; WD40_repeat.
DR   InterPro; IPR036322; WD40_repeat_dom_sf.
DR   PANTHER; PTHR10241; LETHAL 2 GIANT LARVAE PROTEIN; 1.
DR   PANTHER; PTHR10241:SF21; LETHAL(2) GIANT LARVAE PROTEIN HOMOLOG 1; 1.
DR   Pfam; PF08366; LLGL; 1.
DR   Pfam; PF00400; WD40; 1.
DR   PRINTS; PR00962; LETHAL2GIANT.
DR   SMART; SM00320; WD40; 5.
DR   SUPFAM; SSF50978; WD40 repeat-like; 1.
DR   PROSITE; PS00678; WD_REPEATS_1; 2.
DR   PROSITE; PS50082; WD_REPEATS_2; 1.
PE   1: Evidence at protein level;
KW   Cell projection; Cytoplasm; Cytoskeleton; Endosome; Exocytosis;
KW   Golgi apparatus; Membrane; Phosphoprotein; Reference proteome; Repeat;
KW   WD repeat.
FT   CHAIN           1..1064
FT                   /note="Lethal(2) giant larvae protein homolog 1"
FT                   /id="PRO_0000232725"
FT   REPEAT          38..71
FT                   /note="WD 1"
FT   REPEAT          78..119
FT                   /note="WD 2"
FT   REPEAT          139..176
FT                   /note="WD 3"
FT   REPEAT          200..234
FT                   /note="WD 4"
FT   REPEAT          240..272
FT                   /note="WD 5"
FT   REPEAT          290..332
FT                   /note="WD 6"
FT   REPEAT          340..374
FT                   /note="WD 7"
FT   REPEAT          396..474
FT                   /note="WD 8"
FT   REPEAT          518..593
FT                   /note="WD 9"
FT   REPEAT          602..663
FT                   /note="WD 10"
FT   REPEAT          723..783
FT                   /note="WD 11"
FT   REPEAT          792..844
FT                   /note="WD 12"
FT   REPEAT          849..902
FT                   /note="WD 13"
FT   REPEAT          916..939
FT                   /note="WD 14"
FT   REGION          966..1010
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        966..983
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         663
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12725730"
FT   MOD_RES         958
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80Y17"
FT   MOD_RES         967
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80Y17"
FT   MOD_RES         985
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80Y17"
FT   VARIANT         148
FT                   /note="S -> G (in dbSNP:rs2290505)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:7542763, ECO:0000269|PubMed:8565641"
FT                   /id="VAR_058710"
FT   VARIANT         550
FT                   /note="Q -> H (in dbSNP:rs1063683)"
FT                   /evidence="ECO:0000269|PubMed:7542763"
FT                   /id="VAR_058711"
FT   CONFLICT        5
FT                   /note="R -> P (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        152
FT                   /note="A -> G (in Ref. 2; BAA19516)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        159
FT                   /note="S -> SS (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        194
FT                   /note="A -> D (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        206
FT                   /note="R -> Q (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        216
FT                   /note="S -> D (in Ref. 2; BAA19516)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        223
FT                   /note="W -> R (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        226..227
FT                   /note="AS -> SR (in Ref. 2; BAA19516)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        337..338
FT                   /note="TS -> HF (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        400
FT                   /note="H -> Y (in Ref. 2; BAA19516)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        486
FT                   /note="A -> S (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        580
FT                   /note="P -> L (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        588
FT                   /note="Q -> L (in Ref. 2; BAA19516)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        590
FT                   /note="R -> C (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        624..629
FT                   /note="FDYQRK -> L (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        686
FT                   /note="Q -> L (in Ref. 2; BAA19516)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        781..782
FT                   /note="EV -> KE (in Ref. 2; BAA19516)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        782
FT                   /note="V -> L (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        799
FT                   /note="Missing (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        818
FT                   /note="D -> H (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        860
FT                   /note="V -> VV (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        871
FT                   /note="E -> R (in Ref. 2; BAA19516)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        894
FT                   /note="Missing (in Ref. 2; BAA19516)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        898
FT                   /note="Q -> E (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        945
FT                   /note="P -> G (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1060..1064
FT                   /note="AILIK -> CI (in Ref. 1; CAA60130)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1064 AA;  115418 MW;  9318D6736934E4D5 CRC64;
     MMKFRFRRQG ADPQREKLKQ ELFAFNKTVE HGFPNQPSAL AFDPELRIMA IGTRSGAVKI
     YGAPGVEFTG LHRDAATVTQ MHFLTGQGRL LSLLDDSSLH LWEIVHHNGC AHLEEALSFQ
     LPSRPGFDGA SAPLSLTRVT VVLLVAASDI AALGTEGSSV FFLDVTTLTL LEGQTLAPGE
     VLRSVPDDYR CGKALGPVES LQGHLRDPTK ILIGYSRGLL VIWNQASQCV DHIFLGNQQL
     ESLCWGRDSS TVVSSHSDGS YAVWSVDAGS FPTLQPTVAT TPYGPFPCKA INKILWRNCE
     SGGHFIIFSG GMPRASYGDR HCVSVLRAET LVTLDFTSRI IDFFTVHSTR PEDEFDDPQA
     LAVLLEEELV VLDLQTPGWP AVPAPYLAPL HSSAITCSAH VASVPAKLWA RIVSAGEQQS
     PQPVSSALSW PITGGRNLAQ EPSQRGLLLT GHEDGTVRFW DASGVALRPL YKLSTAGLFQ
     TDCEHADSLA QAAEDDWPPF RKVGCFDPYS DDPRLGVQKV ALCKYTAQMV VAGTAGQVLV
     LELSDVPVEQ AVSVAIIDLL QDREGFTWKG HERLSPRTGP LPWPAGFQPR VLVQCLPPAA
     VTAVTLHTEW SLVAFGTSHG FGLFDYQRKS PVLARCTLHP NDSLAMEGPL SRVKSLKKSL
     RQSFRRIRKS RVSGKKRAAN ASSKLQEANA QLAEQACPHD VEMTPVQRRI EPRSADDSLS
     GVVRCLYFAD TFLRDGAHHG PTMWAGTNSG SVFAYALEVP AAAVGGEKRP EQAVEAVLGK
     EVQLMHRAPV VAIAVLDGRG RPLPEPYEAS RDLAQAPDMQ GGHAVLIASE EQFKVFTLPK
     VSAKTKFKLT AHEGCRVRKV ALATFASVAC EDYAETCLAC LTNLGDVHVF SVPGLRPQVH
     YSCIRKEDIS GIASCVFTRH GQGFYLISPS EFERFSLSAR NITEPLCSLD INWPRDATQA
     SYRIRESPKL SQANGTPSIL LAPQSLDGSP DPAHSMGPDT PEPPEAALSP MSIDSATSAD
     TTLDTTGDVT VEDVKDFLGS SEESEKNLRN LAEDEAHACA ILIK
//
